Pregled bibliografske jedinice broj: 207298
Pharmacotherapy of psychotic features of combat related chronic posttraumatic stress disorder
Pharmacotherapy of psychotic features of combat related chronic posttraumatic stress disorder // Zbornik radova- drugi hrvatski kongres o psihofarmakoterapiji s međunarodnim sudjelovanjem / Jakovljević, Miro (ur.).
Zagreb: Medicinska naklada, 2005. str. 44-45 (pozvano predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 207298 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pharmacotherapy of psychotic features of combat related chronic posttraumatic stress disorder
Autori
Kozarić-Kovačić, Dragica
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Zbornik radova- drugi hrvatski kongres o psihofarmakoterapiji s međunarodnim sudjelovanjem
/ Jakovljević, Miro - Zagreb : Medicinska naklada, 2005, 44-45
Skup
Drugi hrvatski kongres o psihofarmakoterapiji s međunarodnim sudjelovanjem
Mjesto i datum
Zagreb, Hrvatska, 03.10.2005. - 07.10.2005
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
pharmacotherapy; psychotic features; combat related chronic posttraumatic stress disorder
Sažetak
Combat-related posttraumatic stress disorder (PTSD) is a severe debilitating psychiatric illness associated with different comorbidities. When complicated with comorbid psychotic features, PTSD is usually refractory to treatment and requires the use of other pharmacotherapeutic strategies, i.e. typical or atypical antipsychotics. In 81 male war veterans with chronic combat related PTSD with psychotic features, treatment response, clinical symptoms and adverse events were assessed using Watson‘ s PTSD questionnaire, Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression (HAMD), Clinical Global Impression Severity Scale (CGI-S), CGI-Improvement (CGI-I), Patient Global Impression Improvement Scale (PGI-I) And Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS). War veterans were treated for 6 weeks with fluphenazine (27 patients), olanzapine (28 patients) in a dose range of 5-10 mg/day, or risperidone (26 patients) in a doses of 2-4 mg/day, as a monotherapy. Treatment with atypical antipsychotic olanzapine or risperidone for 6 weeks improved significantly most of the PTSD and psychotic symptoms in war veterans with combat-related chronic psychotic PTSD. Olanzapine and risperidone showed similar efficacy and tolerability and induced fewer side effects than fluphenazine, suggesting that atypical antipsychotics might have beneficial effects in war veterans with treatment-resistant psychotic PTSD. In an open study the effect of clozapine was evaluated in war veterans with combat-related PTSD complicated with severe insomnia and nightmares: 34 patients were treated for 7 days with clozapine, and 37 patients with sedatives. Clozapine was shown to be efficient in veterans having PTSD as well as in severe sleep disorders and nightmares, due to its strong sedative and anxiolytic effect. Conclusions. Psychotic features in combat related PTSD represent a specific subtype of chronic PTSD and should be included as a distinct nosological entity in the future classifications of mental disorders. Treatment with atypical antipsychotic olanzapine or risperidone for 6 weeks improved significantly most of the PTSD and psychotic symptoms in war veterans with chronic combat-related PTSD. Olanzapine and risperidone showed similar efficacy and tolerability and induced fewer side effects than fluphenazine. Typical antipsychotics might have beneficial effects in war veterans with treatment-resistant psychotic combat-related PTSD. Clozapine was shown to be efficient in veterans having PTSD as well as in severe sleep disorders and nightmares due to its strong sedative and anxiolytic effect.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA